Regulatory requirements in Brazil, ASEAN, CIS and GCC regions MCQs With Answer

Introduction

This quiz collection focuses on regulatory requirements in Brazil, ASEAN, CIS (EAEU) and GCC regions—key topics in the Regulatory Aspects of Drugs & Cosmetics (MRA201T) syllabus for M.Pharm students. It covers regional regulatory authorities, dossier formats, GMP and stability expectations, pharmacovigilance duties, clinical trial and marketing authorization pathways, labeling and local representation requirements. The questions are designed to deepen understanding of practical differences and harmonization efforts (e.g., ACTD, EAEU procedures, GCC-DR and ANVISA processes), preparing students for regulatory strategy, submissions and compliance in these diverse regulatory environments.

Q1. Which authority is the national regulatory agency responsible for drug and cosmetics regulation in Brazil?

• Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Agência Nacional de Vigilância Sanitária (ANVISA)
• Ministry of Health, India

Correct Answer: Agência Nacional de Vigilância Sanitária (ANVISA)

Q2. The ASEAN Common Technical Dossier (ACTD) was developed primarily to:

• Replace the ICH CTD globally
• Provide a harmonized dossier format for pharmaceutical registration across ASEAN member states
• Abolish national requirements in each ASEAN country
• Standardize GMP inspection checklists worldwide

Correct Answer: Provide a harmonized dossier format for pharmaceutical registration across ASEAN member states

Q3. The Eurasian Economic Union (EAEU) unified drug registration system primarily benefits which group of countries?

• Brazil, Argentina and Chile
• Gulf Cooperation Council members
• Russia, Belarus, Kazakhstan, Armenia and Kyrgyzstan
• ASEAN member states

Correct Answer: Russia, Belarus, Kazakhstan, Armenia and Kyrgyzstan

Q4. The Gulf Central Committee for Drug Registration (GCC-DR) mechanism is best described as:

• An initiative to harmonize clinical trial ethics committees in Africa
• A centralized registration route enabling submission of a single dossier for multiple GCC countries
• A pharmacovigilance-only database for Southeast Asia
• An international GMP certification body

Correct Answer: A centralized registration route enabling submission of a single dossier for multiple GCC countries

Q5. For marketing authorization in Brazil, foreign pharmaceutical companies normally must:

• Submit directly with no local representative
• Appoint a local legal representative or national registration holder
• Only supply dossiers in Portuguese without any local contact
• Use the EMA marketing authorisation as automatically valid

Correct Answer: Appoint a local legal representative or national registration holder

Q6. Which dossier format is ASEAN’s ACTD most closely modeled on?

• U.S. New Drug Application (NDA)
• Common Technical Document (CTD) as used by ICH regions
• Brazilian local format only
• WHO generic prequalification dossier exclusively

Correct Answer: Common Technical Document (CTD) as used by ICH regions

Q7. Which module of the CTD/ACTD contains the drug substance and drug product quality information (e.g., manufacturing, control, stability)?

• Module 1
• Module 2
• Module 3
• Module 5

Correct Answer: Module 3

Q8. In Brazil, before beginning a clinical trial, investigators generally must obtain approval from:

• ANVISA and an accredited ethics committee (CEP/CONEP system)
• Only the local hospital director
• GCC-DR central committee
• The European Medicines Agency

Correct Answer: ANVISA and an accredited ethics committee (CEP/CONEP system)

Q9. Which region commonly requires labeling and patient leaflets to be available in Arabic in addition to another language?

• ASEAN
• EAEU
• GCC
• Brazil

Correct Answer: GCC

Q10. A Certificate of Pharmaceutical Product (CPP) is most often used to:

• Demonstrate GMP inspection findings only
• Provide evidence of marketing authorization and GMP status in the country of origin for reliance by other regulators
• Replace stability data requirements for registration
• Act as the manufacturing batch release certificate

Correct Answer: Provide evidence of marketing authorization and GMP status in the country of origin for reliance by other regulators

Q11. Which of the following is a common pharmacovigilance obligation across the Brazil, ASEAN, EAEU and GCC regions?

• There are no reporting requirements for adverse events
• Submission of expedited reports for serious unexpected adverse reactions and periodic safety updates
• Only post-marketing safety inspections, with no need for safety reporting
• Pharmacovigilance is handled solely by international organizations, not local regulators

Correct Answer: Submission of expedited reports for serious unexpected adverse reactions and periodic safety updates

Q12. Which of the following is typically required by regulators in hot and humid regions (e.g., many ASEAN countries) for product registration stability packages?

• Stability studies under ICH Zone I conditions only
• Stability data including climatic Zone IV (hot/humid) conditions
• No stability data if the product is registered elsewhere
• Only accelerated stability testing is accepted

Correct Answer: Stability data including climatic Zone IV (hot/humid) conditions

Q13. Which regulatory pathway is commonly used in GCC and some EAEU submissions to expedite access to products already approved by stringent regulators?

• Local bioequivalence always required regardless of prior approvals
• Reliance or recognition pathways using prior approvals and evaluation reports from stringent regulators
• Compulsory generation of entirely new clinical trials in each member state
• Total exemption from GMP requirements

Correct Answer: Reliance or recognition pathways using prior approvals and evaluation reports from stringent regulators

Q14. For generic drug approval in Brazil and many ASEAN countries, a key study often required to demonstrate interchangeability is:

• Pharmacoeconomic analysis
• Bioequivalence study
• Global multicenter phase III superiority trial
• Only in-vitro dissolution testing with no in-vivo data

Correct Answer: Bioequivalence study

Q15. Which document is most important to demonstrate that a manufacturing site meets Good Manufacturing Practice for regulatory submission?

• Marketing Authorization Certificate
• GMP Certificate or inspection report issued by a recognized regulatory authority
• Product pricing approval
• Clinical trial protocol

Correct Answer: GMP Certificate or inspection report issued by a recognized regulatory authority

Q16. A major objective of regional harmonization initiatives (ASEAN, EAEU, GCC) is to:

• Increase the number of unique national dossier formats
• Reduce regulatory predictability and increase duplicative testing
• Facilitate regulatory convergence to reduce duplication and speed patient access to medicines
• Eliminate all local quality control testing forever

Correct Answer: Facilitate regulatory convergence to reduce duplication and speed patient access to medicines

Q17. In many GCC and ASEAN member states, who is typically responsible for post-approval pharmacovigilance reporting to the regional/national authority?

• The patient only, with no MAH involvement
• The marketing authorization holder (MAH) or local representative
• The international distributor only, irrespective of MAH
• The ethics committee of the hospital where the drug is sold

Correct Answer: The marketing authorization holder (MAH) or local representative

Q18. Which of the following is a common requirement for importing finished drug product samples for registration testing in several of these regions?

• No documentation is needed; samples can be sent freely
• Import permit or customs clearance with supporting documents and sometimes a local importer
• Only an online email notification to the regulator is sufficient
• Samples must be manufactured locally without exceptions

Correct Answer: Import permit or customs clearance with supporting documents and sometimes a local importer

Q19. A “variation” or “post-approval change” in product manufacturing typically requires which of the following in these regulatory systems?

• No notification regardless of the change
• Submission of a change application classified by risk (minor, moderate, major) with supporting documentation
• Automatic approval after 10 years without submission
• Destruction of all existing stock only

Correct Answer: Submission of a change application classified by risk (minor, moderate, major) with supporting documentation

Q20. When preparing a regulatory strategy for simultaneous submissions across Brazil, ASEAN, EAEU and GCC, an important first step is to:

• Assume identical requirements and submit the same dossier without adaptation
• Conduct a gap analysis of regional dossier, labeling, stability, local representation and pharmacovigilance requirements
• Only plan for a single-language dossier (English) everywhere
• Ignore local regulatory timelines and resources

Correct Answer: Conduct a gap analysis of regional dossier, labeling, stability, local representation and pharmacovigilance requirements

Download